JP7780447B2 - 性機能障害のシクロベンザプリン処置 - Google Patents

性機能障害のシクロベンザプリン処置

Info

Publication number
JP7780447B2
JP7780447B2 JP2022562023A JP2022562023A JP7780447B2 JP 7780447 B2 JP7780447 B2 JP 7780447B2 JP 2022562023 A JP2022562023 A JP 2022562023A JP 2022562023 A JP2022562023 A JP 2022562023A JP 7780447 B2 JP7780447 B2 JP 7780447B2
Authority
JP
Japan
Prior art keywords
cyclobenzaprine
pharmaceutical composition
cancer
disorder
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521167A (ja
JP2023521167A5 (enExample
Inventor
メーガン エリザベス パーメンター，
グレゴリー エム． サリバン，
Original Assignee
トニックス ファーマシューティカルズ ホールディング コーポレイション
トニックス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トニックス ファーマシューティカルズ ホールディング コーポレイション, トニックス ファーマシューティカルズ， インコーポレイテッド filed Critical トニックス ファーマシューティカルズ ホールディング コーポレイション
Publication of JP2023521167A publication Critical patent/JP2023521167A/ja
Publication of JP2023521167A5 publication Critical patent/JP2023521167A5/ja
Priority to JP2025172812A priority Critical patent/JP2025185159A/ja
Application granted granted Critical
Publication of JP7780447B2 publication Critical patent/JP7780447B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022562023A 2020-04-08 2021-04-08 性機能障害のシクロベンザプリン処置 Active JP7780447B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025172812A JP2025185159A (ja) 2020-04-08 2025-10-14 性機能障害のシクロベンザプリン処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007251P 2020-04-08 2020-04-08
US63/007,251 2020-04-08
PCT/US2021/026492 WO2021207561A1 (en) 2020-04-08 2021-04-08 Cyclobenzaprine treatment for sexual dysfunction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025172812A Division JP2025185159A (ja) 2020-04-08 2025-10-14 性機能障害のシクロベンザプリン処置

Publications (3)

Publication Number Publication Date
JP2023521167A JP2023521167A (ja) 2023-05-23
JP2023521167A5 JP2023521167A5 (enExample) 2024-04-22
JP7780447B2 true JP7780447B2 (ja) 2025-12-04

Family

ID=75675042

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562023A Active JP7780447B2 (ja) 2020-04-08 2021-04-08 性機能障害のシクロベンザプリン処置
JP2025172812A Pending JP2025185159A (ja) 2020-04-08 2025-10-14 性機能障害のシクロベンザプリン処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025172812A Pending JP2025185159A (ja) 2020-04-08 2025-10-14 性機能障害のシクロベンザプリン処置

Country Status (7)

Country Link
US (1) US20210315841A1 (enExample)
EP (1) EP4132648A1 (enExample)
JP (2) JP7780447B2 (enExample)
CN (1) CN115803088B (enExample)
AU (1) AU2021253592A1 (enExample)
CA (1) CA3179754A1 (enExample)
WO (1) WO2021207561A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023059728A1 (en) * 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
US12370198B2 (en) 2022-07-08 2025-07-29 La Pharmatech Inc Pharmaceutical compositions and methods for treating psychiatric disorders
KR20250086333A (ko) * 2023-12-06 2025-06-13 삼진제약주식회사 약학적 제제 및 이의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043956A1 (en) 1997-03-31 1998-10-08 Eisai Co., Ltd. 1,4-substituted cyclic amine derivatives
JP2014510138A (ja) 2011-04-04 2014-04-24 エスワン バイオファーマ，インコーポレイテッド 治療計画
JP2017532374A (ja) 2014-09-18 2017-11-02 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2020039256A1 (en) 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0013017A (pt) * 1999-08-13 2002-04-16 Vela Pharmaceuticals Inc Usos de composições para o tratamento ou prevenção dos distúrbios do sono usando doses muito baixas de ciclobenzaprina
US6855324B2 (en) * 2000-11-20 2005-02-15 Adrian Sandler Therapeutic placebo enhancement of commonly-used medications
US20060264511A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
SMT201700578T1 (it) * 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
RS63822B1 (sr) * 2012-06-15 2023-01-31 Tonix Pharma Holdings Ltd Kompozicije i postupci za transmukoznu apsorpciju
SMT202400324T1 (it) * 2013-03-15 2024-11-15 Tonix Pharma Ltd Formulazioni eutettiche di ciclobenzaprina cloridrato e mannitolo
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
BR112019010077A2 (pt) * 2016-11-22 2019-10-01 Alkalidx Inc terapias para o tratamento de condições hipocalêmicas e de ineficácia da lidocaína
US11337937B2 (en) * 2018-08-27 2022-05-24 ReJoy TARR receptor agonists for sexual dysfunction

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043956A1 (en) 1997-03-31 1998-10-08 Eisai Co., Ltd. 1,4-substituted cyclic amine derivatives
JP2014510138A (ja) 2011-04-04 2014-04-24 エスワン バイオファーマ，インコーポレイテッド 治療計画
JP2017532374A (ja) 2014-09-18 2017-11-02 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
WO2019116091A1 (en) 2017-12-11 2019-06-20 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
WO2020039256A1 (en) 2018-08-20 2020-02-27 Tonix Pharma Holdings Limited Methods of treating acute stress disorder and posttraumatic stress disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Journal of Sexual Medicine，2017年，Vol.14，pp.1575-1584

Also Published As

Publication number Publication date
CA3179754A1 (en) 2021-10-14
JP2023521167A (ja) 2023-05-23
EP4132648A1 (en) 2023-02-15
CN115803088A (zh) 2023-03-14
WO2021207561A1 (en) 2021-10-14
AU2021253592A1 (en) 2022-11-10
JP2025185159A (ja) 2025-12-18
CN115803088B (zh) 2025-03-21
US20210315841A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
JP2025185159A (ja) 性機能障害のシクロベンザプリン処置
US11707440B2 (en) Esketamine for the treatment of depression
US20240307322A1 (en) Delivery Of Esketamine For The Treatment Of Depression
US20250295674A1 (en) Neuroactive steroids for treatment of cns-related disorders
US11813248B2 (en) NK-1 antagonist compositions and methods for use in treating depression
BRPI0709924A2 (pt) mÉtodo para prevenir ou tratar uma condiÇço decorrente de deficiÊncia de estrogÊnio local
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
JP2023521167A5 (enExample)
BR112020000842A2 (pt) composições e métodos para tratamento do hiv
US20240415789A1 (en) Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
HK40090080B (zh) 性功能障碍的环苯扎林治疗
HK40090080A (zh) 性功能障碍的环苯扎林治疗
US20180369257A1 (en) Selective progesterone receptor modulators (sprm) and stabilized estrogen level in patient
US20250090528A1 (en) Use of complement factor d inhibitor for treatment of lupus nephritis and immunoglobulin a nephropathy
US20240238290A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
WO2025245066A1 (en) Compositions and methods for affecting weight loss, weight management, sexual disorders, well-being, self-esteem, and/or self-confidence
JP2022516482A (ja) うつ病を処置するためのドンペリドン組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251027

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7780447

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150